Abstract
A patient with probable Alzheimer's disease participated in four studies involving cholinergic and combination cholinergic/noradrenergic treatment regimens. This patient demonstrated clinically significant improvement only with the combination of physostigmine and clonidine. The implications of these findings are discussed with regard to strategies for neurotransmitter augmentation therapy for Alzheimer's disease.
| Original language | English |
|---|---|
| Pages (from-to) | 244-248 |
| Number of pages | 5 |
| Journal | American Journal of Geriatric Psychiatry |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1993 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver